Two drugs, one drug class
Both medications belong to the GLP-1 receptor agonist class. Both are FDA-approved for chronic weight management in adults with a BMI of 30+ (or 27+ with a weight-related comorbidity). Both are once-weekly subcutaneous injections. Both work primarily by slowing gastric emptying and acting on the brain's appetite centers.
Where they diverge: Tirzepatide is a dual agonist that hits both the GLP-1 and GIP receptors. Semaglutide hits GLP-1 only. That difference shows up in clinical trial data, side-effect profiles, and how each one feels for the patient in the first 90 days.
Wegovy · Ozempic
- Mechanism: GLP-1 receptor agonist (single pathway)
- Average weight loss: ~15% of total body weight at 68 weeks
- Dose range: 0.25 mg → 2.4 mg weekly
- Typical titration: 16-20 weeks to full dose
- Best for: First-line GLP-1 use, patients with strong response to standard GLP-1, those with insurance coverage tied to Wegovy
Zepbound · Mounjaro
- Mechanism: GLP-1 + GIP dual agonist
- Average weight loss: ~20-22% of total body weight at 72 weeks
- Dose range: 2.5 mg → 15 mg weekly
- Typical titration: 20-24 weeks to full dose
- Best for: Patients who plateau on Semaglutide, those with type 2 diabetes, patients seeking the highest average weight loss
What the trial data actually shows
The headline STEP and SURMOUNT trials anchored the comparison. STEP 1 (Semaglutide 2.4 mg) showed an average 14.9% total body weight loss at 68 weeks vs 2.4% on placebo. SURMOUNT-1 (Tirzepatide 15 mg) showed an average 20.9% at 72 weeks vs 3.1% on placebo.
In practical Mississippi terms: a patient starting at 250 lb on Semaglutide can expect to land near 213 lb after 16-18 months at full titration. The same patient on Tirzepatide can expect to land near 198 lb. Both are clinically meaningful. Both shift A1C, blood pressure, and triglycerides in the right direction. The 5-7% difference matters more for patients with higher starting BMI than for those near the threshold.
Side effects: where they really differ
Both drugs share the GLP-1 GI profile: nausea, constipation, occasional vomiting in the first 4-8 weeks, especially at dose escalations. The majority of patients tolerate it well when titration is slowed.
Tirzepatide's dual agonism gives some patients more pronounced early-phase nausea (the GIP component is a known contributor). It also tends to suppress appetite more aggressively, which can mean patients forget to eat protein. Semaglutide is usually the gentler start, which is why we often begin first-time GLP-1 patients on it.
Less common: gallbladder issues, pancreatitis, and (in family history) MTC concerns. We screen for these in your initial consult.
How we decide between them
The answer is rarely either-or. For most patients we look at:
- Starting BMI: Higher BMI patients tend to get more value from Tirzepatide's extra efficacy.
- Comorbidities: Type 2 diabetes patients often benefit from Tirzepatide's GIP effect on glucose. Patients with reflux or gallbladder history may do better starting with Semaglutide.
- GI tolerance: If your gut is sensitive, start gentler.
- Cost and access: Compounded Semaglutide and Tirzepatide are both available through our network; pricing differences are real but smaller than they used to be.
Common Mississippi patient questions
Can I switch from one to the other?
Yes. Many patients start on Semaglutide and switch to Tirzepatide after 6-9 months if they plateau. We re-titrate from a low Tirzepatide dose to avoid the first-phase nausea.
Will I have to stay on it forever?
Most patients stay on a maintenance dose long-term. Studies show that stopping abruptly leads to regain of about two-thirds of lost weight within a year. We work toward the lowest effective dose, not the highest.
Will insurance cover it in Mississippi?
Coverage varies dramatically. Wegovy and Zepbound are sometimes covered for BMI 30+; Ozempic and Mounjaro generally require a diabetes diagnosis. We help you check coverage before you commit.
Talk to a provider, not an algorithm.
The right GLP-1 for you depends on your labs, your starting weight, your comorbidities, and your gut. We'll review all of it in your first consult.
See us in person
Both medications are dispensed through our three Mississippi clinics. In-person for the initial visit and lab draw, then telehealth follow-up.
This article is educational and does not replace medical advice. GLP-1 medications require provider supervision, lab work, and ongoing monitoring. Speak with a licensed clinician before starting or changing any treatment.